In our sarcoma studies we also discovered that Rubicon knock down was significantly more protective against neratinib, [pazopanib + entinostat] and [pazopanib + entinostat + neratinib] when compared to Beclin1/ATG5. Here, ATG5 is linked to sarcoma.